Biocon

    OverviewSuggest Edit

    Biocon is a biopharmaceutical company focused on delivering healthcare solutions. It manufactures novel biologics, biosimilar insulins, and antibodies. The company aims to reduce therapy costs of diseases such as autoimmune, diabetes and cancer.

    TypePublic
    Founded1978
    HQBengaluru, IN
    Websitebiocon.com
    Employee Ratings3.7

    Latest Updates

    Employees (est.) (Jun 2019)7,995
    Cybersecurity ratingBMore

    Key People/Management at Biocon

    John Shaw

    John Shaw

    Vice Chairman and Non-Executive Director
    Mary Harney

    Mary Harney

    Independent and Non-Executive Director
    Vijay Kuchroo

    Vijay Kuchroo

    Independent and Non-Executive Director
    Ravi Mazumdar

    Ravi Mazumdar

    Non-Executive Director
    M. Damodaran

    M. Damodaran

    Independent and Non-Executive Director
    Siddharth Mittal

    Siddharth Mittal

    CEO and Managing Director
    Show more

    Biocon Office Locations

    Biocon has an office in Bengaluru
    Bengaluru, IN (HQ)
    Hosur Rd
    Show all (1)

    Biocon Online and Social Media Presence

    Embed Graph

    Biocon News and Updates

    Biocon Unit To Offer 15% Stake To Serum Institute’s Arm In A Strategic Alliance

    Adar Poonawalla will have a board seat in Biocon Biologics.

    Insights on the Automated Insulin Delivery System Global Market to 2026 - Featuring Biocon, Dexcom and Digital Medics Among Others

    Dublin, Sept. 14, 2021 (GLOBE NEWSWIRE) -- The "Automated Insulin Delivery System Market Research Report by Disease Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Automated Insulin Delivery System Ma…

    United States Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026, Featuring Biocon, Eli Lilly, HEC Pharma, Mylan and Sanofi

    DUBLIN, Aug. 24, 2021 /PRNewswire/ -- The "US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Highlights: US Diabetic Drug Market Opportunity: > US$ 35 Billion US Insulin Market Opportunity > US$ 10...

    Biocon Q1 Review - Biosimilars Recover; Generics Slip: ICICI Securities

    Biocon Q1 Review - Biosimilars Recover; Generics Slip: ICICI Securities

    Biocon Management On Q1 Result And Growth Strategy For FY22

    Biocon Management On Q1 Result And Growth Strategy For FY22

    Worldwide Human Insulin Industry to 2026 - Key Players Include Biocon, Novo Nordisk and Pfizer Among Others

    Dublin, July 14, 2021 (GLOBE NEWSWIRE) -- The "Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global human insulin market exhibited moderate growth during 2015-2020. Looking forw…
    Show more

    Biocon Blogs

    A Unique & Synergistic Alliance to Impact Global Health

    Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd, have entered into a historic alliance to impact global health. This alliance will complement the strengths and resources of two lea…

    Biocon Biologics Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection

    The post Biocon Biologics Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection appeared first on Biocon.

    Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance

    The post Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance appeared first on Biocon.

    Women With PCOS Need Extra Attention During COVID-19

    Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age (15–49 years). Worldwide, nearly 116 million women (3.4%) are afflicted with this syndrome and in India, around 10% of women are grappling with this syndrome, however, there is a dearth of pro…

    Biocon Limited enters into a settlement agreement with Celgene Corp.

    The post Biocon Limited enters into a settlement agreement with Celgene Corp. appeared first on Biocon.

    Biocon Frequently Asked Questions

    • When was Biocon founded?

      Biocon was founded in 1978.

    • Who are Biocon key executives?

      Biocon's key executives are John Shaw, Mary Harney and Vijay Kuchroo.

    • How many employees does Biocon have?

      Biocon has 7,995 employees.

    • Who are Biocon competitors?

      Competitors of Biocon include Idorsia, Alembic Pharmaceuticals and Cipla.

    • Where is Biocon headquarters?

      Biocon headquarters is located at Hosur Rd, Bengaluru.

    • Where are Biocon offices?

      Biocon has an office in Bengaluru.

    • How many offices does Biocon have?

      Biocon has 1 office.